01—Abstract
Summary
Summary of the 8-K filed June 6, 2024. Cited figures are marked; the original filing is the authoritative source.
BridgeBio Pharma, Inc. (Nasdaq: BBIO) reported in a June 4, 2024 press release, furnished as Exhibit 99.1 to this Current Report under Item 8.01, sustained positive results from Cohort 5 (0.25 mg/kg/day) of PROPEL 2, a Phase 2 trial of oral infigratinib in children with achondroplasia.
Treatment produced a statistically significant and sustained mean increase in annualized height velocity of +2.51 cm/yr from baseline at Month 12 and +2.50 cm/yr at Month 18 (p=0.0015). At Month 18, body proportionality improved, with the mean upper to lower body segment ratio falling to 1.88 from 2.02 at baseline (p=0.001). The company stated that infigratinib remained well-tolerated, with no adverse events assessed as treatment-related in any Cohort 5 participant.
The company said PROPEL 3, its global Phase 3 registrational study of infigratinib in achondroplasia, continues to enroll on schedule, with completion of enrollment anticipated by the end of 2024. BridgeBio also announced it is accelerating development in hypochondroplasia, citing positive interactions with the U.S. FDA and EMA. The first participant was consented in May 2024 into ACCEL, the observational lead-in study.
The planned interventional ACCEL 2/3 program will include an open-label Phase 2 portion in children aged 5 to 11 followed by a pivotal, one-year, 2:1 randomized, double-blinded, placebo-controlled Phase 3 study. The filing is a short notice of a press release.
It does not disclose financial results, financing, or guidance. Investors should note that the data are from a small dose-escalation cohort, and the press release itself lists forward-looking risks, including that initial and ongoing trial data may not be indicative of final data.
02—Key points
Key Highlights
- Cohort 5 of PROPEL 2 (0.25 mg/kg/day) showed a statistically significant, sustained increase in annualized height velocity of +2.51 cm/yr at Month 12 and +2.50 cm/yr at Month 18 (p=0.0015).
- Body proportionality improved at Month 18 (p=0.001), with the mean upper to lower body segment ratio at 1.88 versus 2.02 at baseline.
- No adverse events were assessed as treatment-related in any Cohort 5 participant, per the company.
- PROPEL 3, the global Phase 3 registrational study in achondroplasia, continues to enroll on schedule, with enrollment completion anticipated by the end of 2024.
- BridgeBio is accelerating development of infigratinib in hypochondroplasia following positive interactions with the FDA and EMA.
- The first participant was consented in May 2024 into ACCEL, the observational lead-in study for hypochondroplasia.
- The planned ACCEL 2/3 interventional program includes a pivotal one-year, 2:1 randomized, double-blinded, placebo-controlled Phase 3 study in children aged 3 to under 18 years.
03—Questions
Frequently Asked Questions
What were the main efficacy results for infigratinib in achondroplasia?
In Cohort 5 of PROPEL 2 (0.25 mg/kg/day), the mean change from baseline in annualized height velocity was +2.51 cm/yr at Month 12 and +2.50 cm/yr at Month 18, both statistically significant (p=0.0015). Body proportionality also improved significantly at Month 18 (p=0.001), with the upper to lower body segment ratio at 1.88 versus 2.02 at baseline.
What was the safety profile reported?
The company stated that infigratinib continues to be well-tolerated as a single daily oral therapy, with no adverse events assessed as treatment-related in any Cohort 5 participant. The filing does not provide a broader safety dataset.
When is the Phase 3 PROPEL 3 study expected to complete enrollment?
PROPEL 3, the global Phase 3 registrational study of infigratinib in achondroplasia, continues to enroll on schedule, with completion of enrollment anticipated by the end of 2024.
Why is BridgeBio expanding infigratinib into hypochondroplasia?
The company cited the promising PROPEL 2 results and positive interactions with the U.S. FDA and EMA supporting development in children with hypochondroplasia. The planned program starts with an observational lead-in (ACCEL), with the first participant consented in May 2024, followed by an interventional ACCEL 2/3 study that includes an open-label Phase 2 portion and a pivotal Phase 3 study.
04—Continue